

Higher Comorbidities and Early Death is Characteristic of Hospitalized African-American Patients with COVID-19

Raavi Gupta, M.D., Raag Agrawal, B.A., Zaheer Bukhari, M.D., Absia Jabbar, M.D., Donghai Wang, M.D. Ph.D., John Diks, M.D., Mohamed Alshal, M.D., Dokpe Yvonne Emechebe, M.D., F. Charles Brunnicardi, M.D., Jason M. Lazar, M.D., M.P.H., Robert Chamberlain, M.B.B.S., M.P.H., Aaliya Burza, M.D., M.A. Haseeb, Ph.D.

¹ SUNY Downstate Medical Center, Departments of Pathology and Cell Biology, Brooklyn, New York, (R.G., M.A.H.)

² SUNY Downstate Medical Center, Departments of Pathology (R.A., Z.B., A.J., D.W., J.D., M.A., D.Y.E.)

³ SUNY Downstate Medical Center, Department of Surgery (F.C.B.)

⁴ SUNY Downstate Medical Center, Department of Medicine, Division of Cardiology (J.M.L.)

⁵ SUNY Downstate Medical Center, Department of Anesthesiology (R.C.)

⁶ SUNY Downstate Medical Center, Department of Medicine, Division of Pulmonary Medicine and Critical Care (A.B.)

Correspondence:

Raavi Gupta, M.D.
450 Clarkson Ave. MSC #37,
Brooklyn, NY, 11203
raavi.gupta@downstate.edu

47 **ABSTRACT**

48

49 **Background**

50 African-Americans/Blacks have suffered higher morbidity and mortality from COVID-19
51 than all other racial groups. This study aims to identify the causes of this health
52 disparity, determine prognostic indicators, and assess efficacy of treatment
53 interventions.

54

55 **Method**

56 We performed a retrospective cohort study of clinical features and laboratory data of
57 COVID-19 patients admitted over a five-week period at the height of the pandemic in
58 the United States. This study was performed at an urban academic medical center in
59 New York City, declared a COVID-only facility, serving a majority Black population

60

61 **Result**

62 Of the 1,070 consecutive patients who tested positive for COVID-19, 496 critically ill
63 patients were hospitalized and included in the study. 88% of patients were Black; and a
64 majority (53%) were 61-80 years old with a mean body mass index in the “obese”
65 range. 97% had one or more comorbidities. Hypertension was the most common (84%)
66 pre-existing condition followed by diabetes mellitus (57%) and chronic kidney disease
67 (24%). Patients with chronic kidney disease and end-stage renal disease who received
68 hemodialysis were found to have significantly lower mortality, then those who did not
69 receive it, suggesting benefit from hemodialysis (11%, OR, 0.35, CI, 0.17 - 0.69
70 $P=0.001$). Age >60 years and coronary artery disease were independent predictors of
71 mortality in multivariate analysis. Cox Proportional Hazards modeling for time to death
72 demonstrated a significantly high ratio for COPD/Asthma, and favorable effects on
73 outcomes for pre-admission ACE inhibitors and ARBs. CRP (180, 283 mg/L), LDH
74 (551, 638 U/L), glucose (182, 163 mg/dL), procalcitonin (1.03, 1.68 ng/mL), and
75 neutrophil / lymphocyte ratio (8.5, 10.0) were predictive of mortality on admission and at
76 48-96 hrs. Of the 496 inpatients, 48% died, one third of patients died within the first
77 three days of admission. 54/488 patients received invasive mechanical ventilation, of
78 which 87% died and of the remaining patients, 32% died.

79

80 **CONCLUSIONS**

81 COVID-19 patients in our predominantly Black neighborhood had higher mortality, likely
82 due to higher prevalence of comorbidities. Early dialysis and pre-admission intake of
83 ACE inhibitors/ARBs improved patient outcomes. Early escalation of care based on
84 comorbidities and key laboratory indicators is critical for improving outcomes in African-
85 American patients.

86

87 **Key words:** Health Disparities, COVID-19, African-Americans, Dialysis, ACE Inhibitors,
88 ARBs, Comorbidities, Chronic Kidney Disease

89

90

91

92

93 Background

94
95 Coronavirus Disease 2019 (COVID-19), caused by infection with Severe Acute
96 Respiratory Syndrome Coronavirus-2, has been declared by the World Health
97 Organization to be a pandemic, with over five million confirmed cases.¹ New York became
98 the epicenter of the epidemic in the United States, accounting for more than 23% of the
99 total U.S. cases by the end of May, 2020.² Such burden of disease is of particular concern
100 since it disproportionately affects communities with considerable health disparities, where
101 African-Americans and Latinos constitute as much as 53% of the population.³

102
103 The spectrum of COVID-19 presentation ranges from mild influenza-like illness to life-
104 threatening severe respiratory disease requiring ventilatory support.³ Comorbid
105 conditions such as hypertension, diabetes mellitus, pulmonary and heart diseases, and
106 demographic factors have been reported to influence outcomes.⁴⁻⁶ However, the relative
107 influence of each of these comorbidities in different patient populations and age strata
108 has not been assessed, leading to variability in management and outcomes. Key
109 decisions in patient management such as the choice of antibiotic, blood pressure goals,
110 and perhaps most importantly, airway management strategies, have remained variable
111 across or within hospitals.

112
113 National health statistics have documented extensive health disparities for Black COVID-
114 19 patients. They suffer a three-fold greater infection rate, and a six-fold greater mortality
115 rate than their white counterparts.⁷ However, clinical features and laboratory data of
116 prognostic significance from Black COVID-19 patients remain unexplored and
117 undocumented. A range of cultural, linguistic, and healthcare access barriers have
118 prevented clinical investigation. Our hospital, located in New York City, serves a
119 predominantly Black population, and being declared a COVID-only facility, we were able
120 to maintain a standard quality-of-care across all COVID-19 patients.

121
122 Here we explore the clinical aspects of COVID-19 and its outcomes in Black patients; we
123 also identify comorbidities and demographic factors that help explain the greater mortality
124 from COVID-19 observed in this vulnerable population. This study evaluated clinical signs
125 and symptoms, laboratory indicators, and management strategies to develop a data-
126 driven COVID-19 patient-care approach. We evaluated these factors at admission and at
127 48-96 hours after admission, as one-third of our patients died within the first few days of
128 admission, and we found early recognition of critical indicators pivotal in assessing risk of
129 mortality. To our knowledge, this is the only study that correlates early laboratory
130 indicators at two critical time points with outcomes. Therefore, our findings are expected
131 to provide an evidence-based resource for physicians to assess patient progress within
132 the first three days of hospitalization to direct patient management decisions.

134 Methods

135
136 This study analyzed COVID-19 patients hospitalized at the State University of New York
137 (SUNY), Downstate Medical Center, Brooklyn, New York, that was designated a COVID-
138 only facility by the State of New York as of March 4th, 2020. The hospital is located in a

139 majority Black neighborhood with high rates of poverty.⁸ This study was approved by the
140 SUNY Downstate Institutional Review Board [1587476-1].

141
142 We examined 496 consecutively admitted COVID-19 patients during a five-week period
143 (March-April) when the hospital was under peak caseload and admission was reserved
144 for critically ill patients. COVID-19 diagnosis was based on clinical presentation and a
145 positive real-time reverse transcriptase polymerase chain reaction (rtPCR) from a
146 nasopharyngeal swab (Xpert Xpress SARS-CoV-2, Cepheid, Sunnyvale, CA). Patients
147 were admitted if deemed to be in respiratory distress (respiratory rate >22 breaths/min
148 and in need of supplemental oxygen to maintain oxygen saturation >92%), were
149 encephalopathic, or were judged sufficiently ill to require hospitalization. Only patients
150 with final clinical outcomes, such as discharge or expiration, were included. Patients with
151 “fluid overload” (due to missed dialysis), pregnancy, or those still hospitalized were
152 excluded from this analysis.

153
154 Demographic factors, comorbidities, presenting clinical symptoms, and outcomes
155 (discharge/death) were available for 496 patients. Of these, laboratory data were
156 recorded for 281 patients on admission or within 24 hr of hospitalization, and at a second
157 time point between 48-96 hr post-admission. Pre-admission medications were recorded
158 based on admission medication reconciliation by admitting physicians. Based on self-
159 reported race/ethnicity, patients were grouped into Black and Others (White
160 Hispanic/non-Hispanic and Asian). HIV-positive patients (with low CD4 counts) and
161 transplant recipients were categorized as “immunocompromised”.

162
163 Patients were treated with hydroxychloroquine (200 mg twice a day, for five days) and
164 azithromycin (250 mg once a day, for five days). All patients received standard venous
165 thromboembolism prophylaxis with low-molecular weight heparin or direct oral
166 anticoagulants based on their creatinine clearance rate. Patients with elevated D-dimer
167 received a full dose anticoagulation regimen. Hypoxia, a sign of Acute Respiratory
168 Distress Syndrome (ARDS), was monitored by a continuous pulse oximeter and with
169 arterial blood gas measurements, and supplemental oxygen was provided as needed via
170 noninvasive ventilation. Patients with worsening respiratory distress despite supportive
171 care, as determined by declining pulse oximeter saturation, increasing respiratory rate, or
172 worsening partial pressure of arterial oxygen/percentage of inspired oxygen ratio) were
173 intubated and placed on mechanical ventilation. Patients who developed acute kidney
174 injury (AKI), defined as an absolute increase in serum creatinine greater than or equal to
175 0.3 mg/dL within 48 hr, with oliguria, with or without hyperkalemia and metabolic acidosis,
176 received hemodialysis.

177
178 Computational analysis was conducted using R (ver. 3.6.3).⁹ Continuous variables are
179 presented as median and interquartile range (IQR). Categorical variables such as gender
180 or race are presented as number and percent of patients with 95% confidence intervals
181 (CI). Percentages are expressed based on the available data for the subgroup relative to
182 the total available data for that variable.

183

184 Parametric variables were evaluated through a Shapiro-Wilk test of normality with a
185 significance cutoff of $P<0.01$. Non-parametric variables were compared using Mann-
186 Whitney rank sum test, with 95% CIs reported. Categorical variables were evaluated
187 using the Fisher exact test, and odds ratios (OR) alongside 95% CIs are presented. All
188 tests were two-tailed and statistical significance was defined as $P<0.05$. No multiple
189 testing correction was applied. A multivariate linear regression analysis was performed
190 on comorbidities and demographic factors for mortality, and ORs with 95% CIs are
191 presented. Cox proportional hazards analysis for time to death was conducted on
192 comorbidities, demographic factors, and pre-admission medications (angiotensin-
193 converting enzyme (ACE) inhibitors and/or angiotensin II receptor blockers (ARBs) and
194 hazard ratios with 95% CIs are presented.

195

196 **Results**

197

198 1,070 patients were tested for COVID-19 over a 5-week period. After excluding 292
199 patients who tested negative and 282 who were treated as outpatients, 496 inpatients
200 with positive test results and symptoms consistent with COVID-19 were included in this
201 study.

202

203 **Demographic Information**

204 The median patient age was 70 years (Interquartile Range (IQR), 60 - 78). A majority of
205 patients were in the age range of 61-80 years (53%, 255/483) and a small minority were
206 <40 years old (5%, 25/483). Mortality rates inversely correlated with patient age, with the
207 highest mortality rate recorded for the >80-year age group (65%, 64/99). 88% of the
208 patients were Black (424/481) and the remaining 12% were Other. No difference in
209 mortality rates were found between the two groups. Male-to-female ratio was 1.17:1, with
210 a higher mortality rate for males (53%, 139/260). The mean BMI of patients was 30 kg/m²
211 (obese) and no correlation with mortality was found. A majority of patients (81%, 157/194)
212 never smoked and, while not statistically significant, mortality rate increased with any
213 history of smoking (Table 1).

214

215 **Presenting Signs and Symptoms, Comorbidities, and Pre-admission Medication**

216 Presenting patient complaints grouped based on systemic symptoms were “fever” (42%,
217 headache, weakness, lethargy), respiratory (76%, cough, shortness of breath),
218 gastrointestinal (21%, diarrhea, vomiting), and neurological (16%, altered mental status,
219 seizure, unresponsiveness).

220

221 Comorbidities were present in 97% (484/496) of patients. The most common
222 comorbidities were hypertension (HT) (84%, 406/484) and diabetes mellitus (DM) (57%,
223 276/484), followed by chronic kidney disease (CKD)/end stage renal disease (ESRD)
224 (24%, 117/485), hyperlipidemia (16%, 81/496), history of cancer (9%, 44/482), coronary
225 artery disease (CAD) (8%, 40/496), chronic obstructive pulmonary disease (COPD) (7%,
226 30/451), and asthma (6%, 28/449). These comorbidities showed correlation with
227 increased mortality except for HT. Autoimmune diseases (38/482) did not affect outcomes
228 (Table 2). Patients with CKD/ESRD and on dialysis (11%, 52/485) showed lower mortality
229 ($P=0.001$) than counterparts with CKD/ESRD without dialysis (13%, 65/485). These

230 results are notable considering patients with CKD/ESRD suffered higher mean number
231 of comorbidities (mean 4.2) than other patients (mean 3.3, $P = <0.001$) (Table 3).

232
233 In multivariate analysis, age >60 years and CAD were independent predictors of mortality.
234 Hemodialysis in patients with CKD/ESRD was an independent predictor of lower mortality
235 ($P = 0.007$) (Figure 1). Cox proportional hazards analysis for time to death showed that
236 COPD/Asthma (HR: 1.79, $P = 0.005$) had a significantly higher hazards ratio for death
237 (Figure 2). Additional analysis demonstrated—patients on pre-admission ACE inhibitors
238 (20%, 29/142) and ARBs (25%, 35/142) had a beneficial effect ($P = 0.013$ and 0.036
239 respectively).

240
241 Complications during clinical course in 312 patients were: acute hypoxic respiratory
242 failure (37%), AKI (15%), cardiogenic shock (18%), neurological shock (5%), sepsis (4%),
243 and diabetic ketoacidosis (3%).

244
245 **Laboratory Data**
246 At admission and at 48-96 hr, leukocyte (8.7K/ μ L, 10.6K/ μ L) and neutrophil counts
247 (7.3K/ μ L, 8.9K/ μ L) were higher ($P < 0.001$) and lymphocyte counts (0.8K/ μ L) were lower
248 at 48-96 hr ($P = 0.003$) for non-survivors. The median neutrophil:lymphocyte ratio (NLR)
249 was higher both at admission and at the second time point in patients who did not survive
250 (8.5, 10, $P < 0.001$). Platelet and hemoglobin were marginally decreased but were not
251 significantly different in survivors and non-survivors. Blood urea nitrogen (BUN) (33, 39
252 mg/dL), creatinine (1.7, 1.6 mg/dL), glucose (182, 163 mg/dL), alkaline phosphatase (66,
253 75 U/L), and aspartate aminotransferase (AST) (52, 64 μ L) levels were higher in non-
254 survivors at both time points ($P < 0.001$). Bilirubin and total protein were mildly increased
255 in non-survivors, but were within their respective reference ranges. Albumin (3.4, 2.8
256 g/dL) was lower for non-survivors at both time points ($P < 0.001$). Lactate dehydrogenase
257 (551, 638 U/L), C-reactive protein (180, 283 mg/L), and procalcitonin (1.03, 1.68 ng/mL)
258 showed significantly higher serum levels at admission and at 48-96 hr ($P = < 0.05$) for
259 non-survivors. D-dimer (3.0 mcg/mL, 7.5 times elevation), prothrombin time (PT) (17.2
260 sec), and international normalized ratio (1.4 U) were increased in non-survivors at the
261 second time point ($P < 0.05$). Activated partial thromboplastin time (aPTT) was not found
262 to be different in the two groups (Table 4).

263
264 **Outcomes**
265 Of the 496 hospitalized patients evaluated, 255 survived and 241 (48.5%) died by the end
266 of the study. Of 488 patients examined, 154 received invasive mechanical ventilation, of
267 which 134 (87%) died. Patients who received supplemental oxygen therapy via non-
268 invasive mode suffered a 32% mortality rate (106/334). This also included patients who
269 self-declared “Do Not Intubate” (DNI), “Do not Resuscitate” (DNR) or came to the hospital
270 in severe respiratory distress and died within the first few hours of admission. More than
271 one third of admitted patients died within the first three days of admission (38%, 91/241),
272 which was similar for both Blacks (77/206) and Others (13/32) (Figure 3). Average time
273 to death for ventilated patients was 7.5 days, while for non-ventilated patients it was 6.2
274 days from admission.

275 Discussion

276
277 This study documents the demographic, clinical features, and outcomes for patients
278 admitted with COVID-19 at an urban hospital located in an underserved majority-Black
279 neighborhood. We also identify indicators available to physicians at two early time points
280 of evaluation to predict outcomes and develop management plans for appropriate levels
281 of care.

282
283 The Black patient population in our study faces unique obstacles such as linguistic and
284 cultural barriers to care and understudied comorbidities.^{10,11} Despite reports that African-
285 Americans face significantly greater mortality from COVID-19, recent studies have
286 examined the clinical outcomes in largely East-Asian or Caucasian cohorts.¹⁰ Here, we
287 present an analysis of 496 consecutively hospitalized patients who had been diagnosed
288 with COVID-19 over a 5-week period at the height of the pandemic in New York City, and
289 have either been discharged or died.

290
291 Older age at admission correlated with higher mortality rate, with the 60+ year age group
292 most at risk, and was an independent risk factor for mortality. Males suffered significantly
293 higher mortality than females, despite identical representation at admission. Recent
294 reports of high plasma concentrations of ACE-2, a receptor for coronavirus, in men may
295 account for higher mortality.¹² Our inpatient population had a mean BMI in the “obese”
296 range, higher than the national average; this finding mirrors higher BMI amongst the Black
297 population nationwide.¹³ However, BMI was not an independent predictor of survival;
298 higher BMIs were more commonly seen amongst younger patients. Smoking was less
299 prevalent in our patient population than the national average; 4% were current smokers
300 and 15% had quit.¹⁴ We found smoking to be unrelated to poor outcome.

301
302 The majority (88%) of our patients were Black. Race was not an independent prognostic
303 factor for survival; higher mortality in our patient population can be attributed to a greater
304 number and prevalence of comorbidities common amongst this group. Comorbidities
305 were present in 97% of our patients, and the presence of any comorbidity was a strong
306 predictor of mortality, as noted in other recent studies.^{15,16} HT and DM were the two most
307 prevalent preexisting conditions; prevalence of HT (84%) and DM (57%) was
308 considerably higher than previously reported (up to 63% and 36%, respectively).¹⁷⁻¹⁹ In
309 the multivariate analysis, coronary artery disease was strongly associated with adverse
310 outcome (OR, 2.45, CI, 1.14 - 5.69, $P=0.034$), followed by DM (OR, 1.38, CI, 0.91 - 2.11,
311 $P=0.13$). A 2.5-fold increase in the risk of mortality from COVID-19 in hypertensive
312 patients has been reported, however, this was not discernable in our patients.¹⁸ Although
313 past history of cancer, HT, autoimmune diseases, and immunosuppression were not
314 independent predictors of mortality, the combined effect of these comorbidities on multiple
315 organ systems and resultant dysregulation of the immune system likely increases
316 susceptibility to COVID-19.^{19,20}

317
318 A notable finding in multivariate analysis was that patients with CKD who were dialyzed
319 early in the course of treatment had better outcomes than those who did not. This group
320 consisted of ESRD patients receiving continued dialysis during hospitalization and

321 patients with worsening CKD who were started early on dialysis (OR, 0.37, CI, 0.17 - 0.74,
322 $P=0.007$). These findings are notable considering patients with CKD/ESRD had more
323 comorbidities as compared to all other patients in the study. Early-dialysis stands out as
324 a potentially beneficial treatment option for patients with CKD/ESRD. It is likely that
325 dialysis removes inflammatory mediators, cytokines, and other effector molecules
326 responsible for the end-organ damage. CKD and ESRD were more prevalent in our
327 patient population (24%) than reported in other studies (between 3% to 8.5%), most likely
328 due to complications from HT and DM.^{4,21} Thus, early hemodialysis is critical in Black
329 patients.

330
331 We found laboratory data at admission vital for triaging patients to receive intensive care.
332 CRP, LDH, and procalcitonin were significantly increased at both admission and at 48-96
333 hr in non-survivors. Indicators of AKI, elevated levels of BUN, creatinine, glucose, and
334 reduced levels of bicarbonate or albumin were significant predictors of adverse outcome
335 at both initial and secondary time points. These findings correlate with reported tubular,
336 endothelial, and glomerular capillary loop injury, likely the result of direct injury or systemic
337 hypoxia.²² Hypoproteinemia and hypoalbuminemia in non-survivors may result from renal
338 insufficiency and suboptimal nutritional status in critically-ill patients, or could reflect
339 stressed state.²¹ As reported elsewhere, we found hyperglycemia to be a predictor of
340 adverse outcome in COVID-19 patients, regardless of their history of diabetes.²³
341 Multivariate analysis of laboratory data was not performed due to sample size limitations.

342
343 Peripheral blood analysis showed that a high median NLR at admission and at 48-96 hr
344 was an independent predictor of adverse outcome in COVID-19 patients, as had been
345 reported in other studies.²⁴ The presence of COVID-19 associated coagulopathy (CAC),
346 a condition characterized by elevation in fibrinogen and D-dimer levels, high PT, relatively
347 normal aPTT, and mild thrombocytopenia without evidence of microangiopathy, was
348 confirmed in our study.²⁵ The mechanisms underlying CAC remain poorly understood,
349 but it can possibly result from activation of extrinsic coagulation pathway, leading to
350 excess consumption of Factor-VII following endothelial cell infection by the virus.^{26,27}
351 Elevated D-dimer levels at the second evaluation time point were associated with higher
352 mortality, likely reflecting coagulation activation from sepsis, “cytokine-storm”, or
353 impending organ failure.

354
355 By the end of our 5-week study, 48.5% of the inpatients had died, including 87% of
356 patients who received invasive mechanical ventilation. Reported mortality rates from
357 other retrospective cohort studies ranged from 21% (New York metropolitan area) to 26%
358 (Lombardy region, Italy) and 33% (UK).^{4,6,28} Our mortality rate was elevated relative to
359 other studies, which we believe is due to the largely poor and disadvantaged
360 neighborhood that our hospital serves. Race was not found to be an independent
361 predictor of mortality. The high mortality rate from COVID-19 from this predominantly
362 Black neighborhood demonstrates the large racial disparity in outcomes between these
363 patients and their counterparts elsewhere.

364
365 Our study has limitations. It examined a predominantly Black patient cohort, which makes
366 comparisons to other races and ethnicities difficult to quantify. This study was carried out

367 over a five week period at the height of the pandemic in New York City, admissions were
368 restricted to the most seriously ill and hospital resources were under strain, which may
369 have contributed to an increase in overall mortality rates. As knowledge and
370 understanding of COVID-19 was developing during March and early April, complete
371 laboratory studies were not systematically ordered for all patients.
372

373 **Conclusions**

374
375 In our predominantly Black cohort we have recorded a mortality rate from COVID-19
376 which is significantly greater than that reported in other studies. While race was not an
377 independent predictor of death, this population had a greater burden of comorbidities than
378 the national average and the prevalence of these chronic comorbidities contributed to
379 both disease severity and higher mortality. Our study identified that early escalation of
380 care is important in patients from minority neighborhoods as one third of the admitted
381 patients die within the first three days-of admission. Laboratory indicators at admission
382 are predictors of outcome and can be utilized by physicians to triage patients and monitor
383 disease course. As early dialysis in patients with chronic renal insufficiency showed
384 considerable benefit, we believe early dialysis in patients with renal disease can improve
385 outcomes.
386

387 **Abbreviations**

388 ACE, angiotensin converting enzyme; AKI, Acute Kidney Injury; aPTT, activated partial
389 thromboplastin time; Alk Phosphatase, alkaline phosphatase; ALT, alanine
390 aminotransferase; ARB, angiotensin II receptor blockers; ARDS, acute respiratory
391 distress Syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; BMI,
392 body mass index; CAC, COVID-19 associated coagulopathy; CAD, coronary artery
393 disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
394 pulmonary disease; CRP, C-reactive protein; DM, diabetes mellitus; DNI, do not intubate;
395 DNR, do not resuscitate; ESRD, end stage renal disease; HIV, human immunodeficiency
396 virus; HT, hypertension; INR, international normalized ratio; IQR, interquartile range;
397 LDH, lactate dehydrogenase; NLR, neutrophil:lymphocyte ratio; OR, odds ratio; PT,
398 prothrombin time; rtPCR, real time polymerase chain reaction; SUNY, State University of
399 New York; UK, United Kingdom.
400

401 **Legends to Tables and Figures**

402
403 **Figure 1.** Multivariate logistic regression analysis of the demographic characteristics and
404 comorbidities for mortality. The 95% confidence intervals (CIs) of the odds ratios have not
405 been adjusted for multiple testing and thus do not suggest definitive effects. BMI, body-
406 mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease;
407 ESRD, end-stage renal disease.
408

409 **Figure 2.** Cox Proportional Hazards analysis on time to death, performed on demographic
410 characteristics and comorbidities.
411

412 **Figure 3.** Days from admission to death of 241 consecutive inpatients. More than one
413 third of patients (91/241) died within three days of admission for both Blacks (77/206) and
414 others (13/32). Race was not recorded in 15 patients.

415
416 **Table 1.** Demographic characteristics of patients admitted for treatment. The *P value* is
417 calculated between patients who survived and did not survive. BMI, body-mass index; CI,
418 confidence interval

419
420 **Table 2.** Comorbidities among patients admitted for treatment. The *P value* is calculated
421 between patients who survived and did not survive. CKD, chronic kidney disease; COPD,
422 chronic obstructive pulmonary disease; ESRD, end-stage renal disease

423
424 **Table 3.** Patients with CKD and/or ESRD had a higher mean number of comorbidities
425 than all patients. CKD, Chronic kidney disease; ESRD, end-stage renal disease.

426
427 **Table 4.** Laboratory data of 281 inpatients at admission and at a secondary time point
428 between 48 and 96 hours of admission. Median and interquartile ranges are presented.
429 The *P value* is calculated between patients who survived and did not survive. aPTT,
430 activated partial thromboplastin time; Alk Phosphatase, alkaline phosphatase; ALT,
431 alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen;
432 CI, confidence interval; CRP, C-reactive protein; INR, international normalized ratio; LDH,
433 lactate dehydrogenase; PT, prothrombin time.

434 435 **Declarations**

436
437 **Ethics Approval and Consent to Participate:** SUNY Downstate Institutional Review
438 Board [1587476-1].

439 **Consent for Publication:** Not applicable

440 **Availability of Data and Materials:** The datasets used and/or analyzed during the
441 current study are available from the corresponding author on reasonable request.

442 **Competing Interests:** The authors declare that they have no competing interests

443 **Funding:** Not applicable

444 **Author Contributions:** RG and MAH conceived and designed the study. RG, RA, and
445 MAH designed the statistical analysis plan. RG, RA, and MAH analyzed the data and
446 developed the figures and tables. RG, ZB, AJ, DW, JD, MA, and DYE collected data
447 from electronic health records. CFB, JL, RC, and AB provided clinical consultation
448 throughout the study course. All authors contributed intellectual content during the
449 drafting and revision of the work and approved the final version.

450 **Acknowledgements:** Not applicable

451
452
453
454
455

References

1. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2020 May 23]. Available from: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>
2. Cases in the U.S. | CDC [Internet]. [cited 2020 May 16]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>
3. U.S. Census Bureau QuickFacts: New York city, New York [Internet]. [cited 2020 May 28]. Available from: <https://www.census.gov/quickfacts/newyorkcitynewyork>
4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* [Internet]. 2020 Apr 22 [cited 2020 Apr 23]; Available from: <http://jamanetwork.com/journals/jama/fullarticle/2765184>
5. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020 26;368:m1091.
6. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv* [Internet]. 2020 Apr 28 [cited 2020 May 23];2020.04.23.20076042. Available from: <https://www.medrxiv.org/content/10.1101/2020.04.23.20076042v1>
7. Yancy CW. COVID-19 and African Americans. *JAMA*. 2020 Apr 15;
8. East Flatbush Neighborhood Profile [Internet]. [cited 2020 May 23]. Available from: <https://furmancenter.org/neighborhoods/view/east-flatbush>
9. R: The R Project for Statistical Computing [Internet]. [cited 2020 Apr 23]. Available from: <https://www.r-project.org/>
10. Dorn A van, Cooney RE, Sabin ML. COVID-19 exacerbating inequalities in the US. *The Lancet* [Internet]. 2020 Apr 18 [cited 2020 May 15];395(10232):1243–4. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30893-X/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30893-X/abstract)
11. Laurencin CT, McClinton A. The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities. *J Racial Ethn Health Disparities* [Internet]. 2020 Apr 18 [cited 2020 May 15];1–5. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166096/>
12. Sama IE, Ravera A, Santema BT, van Goor H, ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. *Eur Heart J* [Internet]. 2020 May 14 [cited 2020 May 16];41(19):1810–7. Available from: <http://academic.oup.com/eurheartj/article/41/19/1810/5834647>
13. Fryar CD, Kruszon-Moran D, Gu Q, Ogden CL. Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States, 1999-2000 Through 2015-2016. *Natl Health Stat Rep*. 2018;(122):1–16.
14. Creamer MR. Tobacco Product Use and Cessation Indicators Among Adults — United States, 2018. *MMWR Morb Mortal Wkly Rep* [Internet]. 2019 [cited 2020 May 15];68. Available from: <http://www.cdc.gov/mmwr/volumes/68/wr/mm6845a2.htm>

15. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging*. 2020 Apr 8;12(7):6049–57.
16. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J* [Internet]. 2020 Jan 1 [cited 2020 May 16]; Available from: <https://erj.ersjournals.com/content/early/2020/03/17/13993003.00547-2020>
17. Garg S. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep* [Internet]. 2020 [cited 2020 May 16];69. Available from: <https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm>
18. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. *Pol Arch Intern Med*. 2020 30;130(4):304–9.
19. Leoncini G, Viazzi F, Storace G, Deferrari G, Pontremoli R. Blood pressure variability and multiple organ damage in primary hypertension. *J Hum Hypertens*. 2013 Nov;27(11):663–70.
20. Restrepo MI, Sibila O, Anzueto A. Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. *Tuberc Respir Dis*. 2018 Jul;81(3):187–97.
21. Su H, Yang M, Wan C, Yi L-X, Tang F, Zhu H-Y, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney Int* [Internet]. 2020 Apr 9 [cited 2020 May 16];0(0). Available from: [https://www.kidney-international.org/article/S0085-2538\(20\)30369-0/abstract](https://www.kidney-international.org/article/S0085-2538(20)30369-0/abstract)
22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet Lond Engl*. 2020 15;395(10223):497–506.
23. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol*. 2020 Apr 12;
24. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect*. 2020 Apr 10;
25. COVID-19 and Coagulopathy - Hematology.org [Internet]. [cited 2020 May 16]. Available from: <https://www.hematology.org:443/covid-19/covid-19-and-coagulopathy>
26. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation*. 2005 May 24;111(20):2605–10.
27. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet Lond Engl*. 2020 02;395(10234):1417–8.
28. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020 06;

Table 1. Demographic Characteristics of COVID-19 inpatients.

Variable	Patients	Survivors	Non-survivors	Odds Ratio (95% CI)	P value
Age - median	70	66	73.5	NA (-10.00 - -5.00)	<0.001
<i>Age ranges</i>	<i>No./total no. (%)</i>	<i>no. (%)</i>	<i>no. (%)</i>		
+80 yr.	99/483(20)	35 (35)	64 (65)	2.20 (1.36 - 3.60)	<0.001
71-80 yr.	131/483(27)	53 (40)	78 (60)	1.76 (1.15 - 2.71)	<0.001
61-70 yr.	124/483(26)	63 (51)	61 (49)	0.99 (0.64 - 1.52)	0.84
51-60 yr.	66/483(14)	46 (70)	20 (30)	0.39 (0.21 - 0.71)	<0.001
41-50 yr.	38/483 (8)	27 (71)	11 (29)	0.39 (0.17- 0.84)	0.003
0-40 yr.	25/483 (5)	21 (84)	4 (16)	0.18 (0.04 - 0.55)	<0.001
<i>Race/Ethnicity</i>	<i>no./total no. (%)</i>	<i>no. (%)</i>	<i>no. (%)</i>		
Black	424/481 (88)	218 (51)	206 (49)	0.73 (0.40 - 1.33)	0.32
Others	57/481 (12)	25 (44)	32 (56)	1.35 (0.74 - 2.47)	0.32
<i>Sex</i>	<i>no./total no. (%)</i>	<i>no. (%)</i>	<i>no. (%)</i>		
Male	260/482 (54)	121 (47)	139 (53)	1.45 (0.99 - 2.11)	0.44
Female	222/482 (46)	124 (56)	98 (44)	0.68 (0.47 - 1.00)	0.44
<i>BMI mean</i>	30	31	29	NA (-2.60 - 1.00)	0.40
<i>BMI</i>	<i>no./total no. (%)</i>	<i>no. (%)</i>	<i>no. (%)</i>		
<29.9	132/235 (56)	45 (34)	87 (66)	1.32 (0.75 - 2.34)	0.34
>30	103/235 (44)	42 (40)	61 (60)	0.75 (0.43 - 1.32)	0.34
<i>Smoking Status</i>	<i>no./total no. (%)</i>	<i>no. (%)</i>	<i>no. (%)</i>		
Non-smoker	157/193 (81)	80 (51)	77 (49)	0.73 (0.33 - 1.60)	0.46
Past/current smoker	36/193(19)	15 (42)	21 (58)	1.46 (0.66 - 3.30)	0.35

Table 2. Comorbidities in COVID-19 inpatients.

Comorbidities	All Patients no./total (%)	Survivors no. (%)	Non- survivors no. (%)	Odds Ratio (95% CI)	P value
Asthma	28/449 (6)	9 (32)	19 (68)	2.44 (1.02 - 6.27)	0.03
Autoimmune disease	38/482 (8)	22 (58)	16 (42)	0.77 (0.36 - 1.59)	0.50
History of cancer	44/482 (9)	14 (32)	30 (68)	2.52 (1.25 - 5.29)	<0.001
COPD	30/451 (7)	14 (47)	16 (53)	1.32 (0.58 - 3.01)	0.057
Coronary Artery Disease	40/496 (8)	10 (25)	30 (75)	3.47 (1.60 - 8.16)	<0.001
Congestive Heart Failure	22/496 (4)	13 (59)	9 (41)	0.72 (0.26 - 1.86)	0.51
CKD without dialysis	65/485 (13)	24 (37)	41 (63)	2.01 (1.14 - 3.61)	0.011
CKD/ESRD with dialysis	52/485 (11)	38 (73)	14 (27)	0.35 (0.17 - 0.69)	0.001
Diabetes mellitus	276/484 (57)	132 (48)	144 (52)	1.48 (1.01 - 2.17)	0.03
Hyperlipidemia	81/496 (16)	34 (42)	47 (58)	1.57 (0.94 - 2.63)	0.06
Hypertension	406/484 (84)	207 (51)	199 (49)	1.31 (0.78 - 2.21)	0.32
Immune suppression	40/475 (8)	26 (65)	14 (35)	0.55 (0.25 - 1.13)	0.09
All patients ≥ 1 Comorbidities	484/496 (97)	252/255 (99)	232/241 (96)	-	-

Table 3. Mean number of comorbidities in patients with chronic kidney diseases and/or end-stage renal disease relative to all patients

Patient group (no.)	Comorbidities (mean)	P value
CKD/ESRD (117/485)	4.2	<0.001
All patients (485)	3.3	

Table 4. Laboratory Data at admission and at a secondary time point between 48 and 96 hours of admission in hospitalized patients.

Laboratory values (reference range)	Time of determination (n)	Survivors	Non-survivors	95% CI	P value
		Median (Inter Quartile Range)			
Hematologic parameters					
Hemoglobin (12-16 g/dL)	At admission (281)	12.3(11.0 -14.0)	12.7 (11.3-14.3)	-0.9 - 0.1	0.13
	48 - 96 hr (224)	12.0 (10.15 - 13.1)	11.7 (10.5-13.3)	-0.6 - 0.5	0.83
Leukocyte count (3.5-10.8 K/ μ L)	At admission (280)	7.1 (5.4 - 9.3)	8.7 (6.5-11.4)	-2.4 - -0.7	<0.001
	48 - 96 hr (224)	6.5 (5.1-9.4)	10.6 (7.8-14.3)	-4.9 - -2.7	<0.001
Neutrophil Count (1.7 - 7 K/ μ L)	on admission (265)	5.8 (3.8-7.8)	7.3 (4.9-10.0)	-2.5 - -0.9	<0.001
	48 - 96 hr (201)	5.4 (3.4-7.6)	8.9 (6.4-12.5)	-4.8, - 2.5	<0.001
Lymphocyte count (0.9-2.9 K/ μ L)	on admission (255)	0.9 (0.7-1.1)	0.8 (0.6-1.1)	-5.4e - -5, 0.2	0.06
	48 - 96 hr(201)	1.0 (0.8-1.3)	0.8 (0.5-1.2)	0.1 - 0.3	0.003
Neutrophil Lymphocyte count (NLR)	on admission (255)	5.4 (3.7-8.1)	8.5 (5.3-13.9)	-3.9 - -1.5	<0.001
	48 - 96 hr (200)	4.7 (3.3-7.0)	10.0 (6.3-19.5)	-7.1 - -3.5	<0.001
Eosinophil count (0.0-0.8 K/ μ L)	on admission (250)	0.03 (0.01-0.07)	0.01 (0.01-0.04)	0.01 - 0.02	<0.001
	48 - 96 hr (199)	0.05 (0.02-0.1)	0.01 (0.01-0.04)	0.01 - 0.03	<0.001
Platelet count	on admission (278)	204 (160-267)	201 (148-263)	-13.0 - 26.9	0.48

<i>(130-400 K/μL)</i>	48 – 96 hr (221)	231 (153-340)	199 (150-280)	-7.0 - 53.9	0.12
Blood Chemistry					
Sodium <i>(136-145 mmol/L)</i>	on admission (282)	136 (133-138)	135 (132-141)	-2.0 - 1.0	0.51
	48 – 96 hr (232)	138 (136-140)	142 (137-147)	-5.9 - -2.0	<0.001
Potassium <i>(3.5-5.1 mmol/L)</i>	on admission (281)	4.2 (3.8-4.8)	4.4 (3.9-5.0)	-0.4 - 4.9e-5	0.05
	48 – 96 hr (230)	4.3 (4.0-4.6)	4.4 (3.9-5)	-0.4 - 5.2e-5	0.05
Bicarbonate <i>(23.0-28.0 mmol/L)</i>	on admission (194)	25 (22-30)	22 (19-26)	1.0 - 4.9	0.001
	48 – 96 hr (141)	24 (21-28)	21 (18-24)	1.6 - 5.0	<.0.001
Chloride <i>(98-107 mmol/L)</i>	on admission (280)	100 (94-103)	100 (96-105)	-3.9 - 3.5e-5	0.09
	48 – 96 hr (230)	102 (96-106)	107 (102-113)	-8.0 - -3.0	<0.001
Magnesium <i>(1.9-2.7 mg/dL)</i>	on admission (155)	2 (1.8-2.2)	2.2 (1.9-2.6)	-0.30 - -2.9e-5	0.014
	48 – 96 hr (160)	2.2 (1.8-2.3)	2.4 (2.1-2.7)	-0.4 - -0.2	<0.001
BUN <i>(7-25 mg/dL)</i>	on admission (280)	22 (14-37)	33 (19-54)	-14.0 - -5.0	<0.001
	48 – 96 hr (230)	19 (13-39)	39 (23-66)	-22.0 - -10	<0.001
Serum creatinine <i>(0.7-1.3 mg/dL)</i>	on admission (281)	1.2 (1.0-2.3)	1.7 (1.2-2.5)	-0.5 - -0.1	0.008
	48 – 96 hr (232)	1.2 (0.8-2.2)	1.6 (1.1-2.9)	-0.6 - -0.1	0.003
Glucose – random <i>(70-99 mg/dL)</i>	on admission (281)	128 (104-184)	182 (129-275)	-61.0 - -23.0	<0.001
	48 – 96 hr (235)	103 (84-140)	163 (119-269)	-72.9 - -35.9	<0.001
AST <i>(13-39 μ/L)</i>	on admission (279)	40 (26-65)	52 (38-83)	-19.0 - -5.0	<0.001
	48 – 96 hr (219)	49 (28-66)	64 (37.7-106.2)	-29.0 - -8.0	<0.001
ALT <i>(7-52 μ/L)</i>	on admission (286)	24 (16-38)	29 (19-44)	-7.0 - 0.1	0.11
	48 – 96 hr (219)	28 (17-52)	34 (22-57)	-10.0 - 2.0	0.22
Alk Phosphatase <i>(34-104 U/L)</i>	on admission (279)	64 (49-78)	66 (54-96)	-15.0 - -1.0	0.02
	48 – 96 hr (218)	59 (46-78)	75 (52-111)	-27.0 - -7.0	<0.001
Bilirubin <i>(0.3-1 mg/dL)</i>	on admission (275)	0.5 (0.4-0.8)	0.6 (0.5-0.8)	-0.1 - 5.0e-5	0.28
	48 – 96 hr (214)	0.5 (0.4-0.8)	0.7 (0.5-.9)	-0.2 - -5.4e-5	0.002
Total protein	on admission (277)	7 (6.5-7.3)	6.7 (6.4-7.2)	-2.6e-5 - 0.3	0.12

(6-8.3 g/dL)	48 – 96 hr (214)	6.2 (5.9-6.6)	6 (5.5-6.7)	-6.0e-5 - 0.4	0.10
Albumin (3.5 - 5.7 g/dL)	on admission (278)	3.6 (3.2-4.0)	3.4 (3.1-3.6)	0.1 - 0.3	<0.001
	48 – 96 hr (218)	3.0 (2.7-3.2)	2.8 (2.5-3.0)	0.1 - 0.3	<0.001
LDH (14-271 U/L)	on admission (201)	379 (280-500)	551 (411-743)	106.0 - 22849	<0.001
	48 – 96 hr (82)	406 (278-553)	638 (444.5-867)	106.9 - 339.0	<0.001
CRP (<10 mg/L)	on admission (201)	117 (63-197)	180 (128-283)	-97.0 - -36.9	<0.001
	48 – 96 hr (85)	96 (41-185)	283 (188-338)	-200.0 - - 88.9	<0.001
Troponin I (≤0.15 ng/mL)	on admission (170)	0.03 (0.02-0.12)	0.08 (0.02-0.21)	3.6e-5 - 0.06	0.010
	48 – 96 hr (61)	0.11 (0.02-0.26)	0.15 (0.06-0.40)	-0.03 - 0.18	0.30
Ferritin (14-233 ng/mL)	on admission (190)	654.5 (303-1151)	955 (539.0-2114.6)	118.5 - 566.5	0.002
	48 – 96 hr (95)	768.5 (439-1821)	1614.1 (499.7- 2801.5)	-37.3, - 1036.7	0.08
Procalcitonin (0-0.10 ng/mL)	on admission(172)	0.32 (0.10-0.96)	1.03 (0.36-3.78)	0.19 - 0.88	<0.001
	48 – 96 hr (69)	0.34 (0.25-2.47)	1.68 (0.41-7.35)	4.75e-5 - 2.77	0.049
D-dimer <0.4 mcg/ml	on admission (50)	3.3 (1.3-5.2)	1.5 (0.5-5.2)	-1.02 - 2.6	0.39
	48 – 96 hr (43)	0.5 (0.5-1.5)	3.0 (1.1-7.5)	-4.5 - -0.2	<0.001
Coagulation Parameters					
aPTT (25.4-38.6 sec)	on admission (126)	29.9 (28.4-32.4)	29.0 (26.9-33.6)	-1.9 - 1.5	0.68
	48 – 96 hr (44)	30.7 (28.0-36.2)	31.1 (27.9-39.0)	-6.3 - 6.3	0.99
PT (10.8-13.7 sec)	on admission (113)	13.0 (12.2-13.7)	13.5 (12.6-15.4)	5.1 - 1.3	0.04
	48 – 96 hr(43)	13.1 (11.9-15.2)	17.2 (13.3-20.2)	4.94e-5 - 6.7	0.04
INR (1 U)	on admission (113)	1.1 (1.0-1.1)	1.1 (1.0-1.3)	-7.12e-6 - 0.10	0.07
	48 – 96 hr (41)	1.0(1.0-1.2)	1.4 (1.1-1.6)	7.49e-6 - 0.50	0.02

Figure 1.

Variable	N	Odds ratio	p
Race	Black	400	Reference
	Other	52	1.47 (0.78, 2.81)
Age > 60	452	2.50 (1.52, 4.18)	<0.001
Sex	Male	205	Reference
	Female	247	1.43 (0.95, 2.15)
Coronary Artery Disease	452	2.45 (1.14, 5.69)	0.028
Hyperlipidemia	452	1.21 (0.71, 2.09)	0.477
Diabetes	452	1.38 (0.91, 2.11)	0.133
Hypertension	452	0.96 (0.53, 1.74)	0.890
COPD/Asthma	452	1.56 (0.84, 2.92)	0.161
Autoimmune Diseases	452	0.94 (0.43, 2.04)	0.871
History of Cancer	452	1.87 (0.92, 3.97)	0.089
Immunocompromised	452	0.79 (0.30, 1.96)	0.612
CKD/ESRD with Dialysis	452	0.37 (0.17, 0.74)	0.007
Congestive Heart Failure	452	0.92 (0.34, 2.40)	0.859

Figure 2.

Variable	N	Hazard ratio	p
Race	Black	191	Reference
	Other	30	1.08 (0.72, 1.62)
Age	221	1.01 (1.00, 1.03)	0.078
Sex	Male	91	Reference
	Female	130	0.83 (0.61, 1.11)
Coronary Artery Disease	221	1.04 (0.64, 1.68)	0.882
Hyperlipidemia	221	1.29 (0.90, 1.85)	0.171
Diabetes	221	1.07 (0.79, 1.44)	0.670
Hypertension	221	1.05 (0.70, 1.59)	0.814
COPD/Asthma	221	1.79 (1.20, 2.68)	0.005
Autoimmune Diseases	221	0.89 (0.51, 1.56)	0.685
History of Cancer	221	0.99 (0.65, 1.51)	0.970
Immunocompromised	221	1.27 (0.59, 2.73)	0.543
CKD/ESRD with Dialysis	221	0.51 (0.25, 1.06)	0.070
Congestive Heart Failure	221	1.19 (0.55, 2.57)	0.653

Figure 3.

